📊 Midday Market Take

Hey, happy Tuesday, and the afternoon session is giving us a bit of a reset as all three major indices are sitting in the red. The S&P 500 is down a quarter percent, the Nasdaq is slipping nearly six tenths, and the Dow is off about a third of a percent as we head through midday.

Tech is the sector worth keeping your eye on right now, with the Nasdaq leading the pullback and growth names feeling the most pressure. If you have exposure to big tech, this dip is worth watching closely, but do not rush to add just yet, because the next hour of trading could clarify whether this is a brief soft patch or something with a little more bite.

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.

3 Reasons to Watch AGIO

• FDA Priority Review Puts Mitapivat in the Spotlight. The FDA just granted priority review to Agios' supplemental new drug application for mitapivat in sickle cell disease, a meaningful regulatory win that accelerates the timeline toward a potential approval decision. This is the kind catalyst that can reset how the market values a biotech, and investors will be watching closely to see if Tuesday's 16% surge holds or invites profit-taking.
• A 54% Monthly Run Is Impossible to Ignore. Agios is up more than 54% over the past 30 days, and Tuesday's pop added another 16% on top of that already extended move. That kind of momentum draws both buyers chasing the breakout and sellers looking to lock in gains, so the near-term price action after this news-driven surge will tell you a lot about where conviction really stands.
• Sickle Cell Program Could Expand PYRUKYND's Market Dramatically. PYRUKYND is already approved for pyruvate kinase deficiency in adults, but a successful path through FDA review for sickle cell disease would open the drug up to a far larger patient population. Sickle cell affects hundreds of thousands of people in the U.S. alone, and a second approved indication would be a significant commercial inflection point for the company.

Top Market Headlines

AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise?

Insiders are selling three key names involved in very different parts of the artificial intelligence (AI) value chain.

Get a piece of OpenAI pre-IPO (Ad)

There's a single ticker that gives you a stake in both OpenAI and Anthropic… You don't have to wait for these revolutionary AI companies to go public. You can get in today, from any regular brokerage account, for less than $100. We'll give you the ticker symbol, completely free. No subscription required.

3 Quantum Computing Stocks to Watch in the Second Half of 2026

Some research suggests quantum computing could generate trillions in economic value in the coming decades.

3 AI Stocks That Could Outperform the S&P 500 for Years to Come

Tech companies can't get enough of Micron Technology's memory processors.

2026 Is Already Setting the Stage — These 3 Names Caught Our Eye (Ad)

The biggest market opportunities don't wait for headlines — by the time the news breaks, the real move is often over. That's why we do the work early, and right now we're watching three small-cap companies that align with conditions historically preceding major market attention in 2026.

Best Income Stocks to Buy for July 7th

BBDC, DEC and TX made it to the Zacks Rank #1 (Strong Buy) income stocks list on July 7, 2026.

A New Market Theme Is Taking Shape for 2026 (Ad)

Major market shifts rarely start where most people are looking — they begin quietly, in smaller companies that support and enable the bigger themes before anyone's paying attention. Right now, several large-scale innovation themes are re-entering the conversation for 2026, and we've identified the small-caps most likely to move first as that attention spreads.

📈 Also Trending

Better than SpaceX? Grab this ticker instead. (Ad)

Larry Benedict generated $274 million for his clients by finding the trade most missed. He says The Final Phase of Elon's Master Plan is about to trigger one of the biggest wealth transfers in market history. He's already identified the ONE ticker positioned to capture it. It isn't SpaceX, Tesla, or...

Click here to get the full details before the window closes.

It's one of Trump's biggest holdings. Do you own it? (Ad)

President Trump owns up to $5 million in shares of this AI company (not Nvidia or SpaceX). He's strongly endorsed its leadership and products. And he just awarded it with a nearly $10 billion Pentagon contract. No wonder one legendary fund manager says it could become the cornerstone of your retirem...

Click here for its name and ticker.

Missed the Gold Boom? Think Again (Ad)

We found a $15 fund tied to gold that is delivering 64% in annual distributions. And the next payout is just days away.

Click to see how to secure the next payout.